Severe COVID-19, multisystem inflammatory syndrome in children, and Kawasaki disease: immunological mechanisms, clinical manifestations and management
Abstract Multisystem inflammatory syndrome (MIS-C) is a pediatric hyperinflammation disorder caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). It has now been reported from several countries the world over. Some of the clinical manifestations of MIS-C mimic Kawasaki disease (KD) shock syndrome. MIS-C develops 4–6 weeks following SARS-CoV-2 infection, and is presumably initiated by adaptive immune response. Though it has multisystem involvement, it is the cardiovascular manifestations that are most prominent. High titres of anti-SARS-CoV-2 antibodies are seen in these patients. As this is a new disease entity, its immunopathogenesis is not fully elucidated. Whether it has some overlap with KD is still unclear. Current treatment guidelines recommend use of intravenous immunoglobulin and high-dose corticosteroids as first-line treatment. Mortality rates of MIS-C are lower compared to adult forms of severe COVID-19 disease..
Medienart: |
Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:41 |
---|---|
Enthalten in: |
Rheumatology international - 41(2020), 1 vom: 21. Nov., Seite 19-32 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Kabeerdoss, Jayakanthan [VerfasserIn] |
---|
Links: |
Volltext [lizenzpflichtig] |
---|
Themen: |
Coronavirus disease 2019 |
---|
Anmerkungen: |
© Springer-Verlag GmbH Germany, part of Springer Nature 2020 |
---|
doi: |
10.1007/s00296-020-04749-4 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
OLC2122667052 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | OLC2122667052 | ||
003 | DE-627 | ||
005 | 20230505064630.0 | ||
007 | tu | ||
008 | 230505s2020 xx ||||| 00| ||eng c | ||
024 | 7 | |a 10.1007/s00296-020-04749-4 |2 doi | |
035 | |a (DE-627)OLC2122667052 | ||
035 | |a (DE-He213)s00296-020-04749-4-p | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | 4 | |a 610 |q VZ |
100 | 1 | |a Kabeerdoss, Jayakanthan |e verfasserin |0 (orcid)0000-0002-7852-6657 |4 aut | |
245 | 1 | 0 | |a Severe COVID-19, multisystem inflammatory syndrome in children, and Kawasaki disease: immunological mechanisms, clinical manifestations and management |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
338 | |a Band |b nc |2 rdacarrier | ||
500 | |a © Springer-Verlag GmbH Germany, part of Springer Nature 2020 | ||
520 | |a Abstract Multisystem inflammatory syndrome (MIS-C) is a pediatric hyperinflammation disorder caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). It has now been reported from several countries the world over. Some of the clinical manifestations of MIS-C mimic Kawasaki disease (KD) shock syndrome. MIS-C develops 4–6 weeks following SARS-CoV-2 infection, and is presumably initiated by adaptive immune response. Though it has multisystem involvement, it is the cardiovascular manifestations that are most prominent. High titres of anti-SARS-CoV-2 antibodies are seen in these patients. As this is a new disease entity, its immunopathogenesis is not fully elucidated. Whether it has some overlap with KD is still unclear. Current treatment guidelines recommend use of intravenous immunoglobulin and high-dose corticosteroids as first-line treatment. Mortality rates of MIS-C are lower compared to adult forms of severe COVID-19 disease. | ||
650 | 4 | |a Multisystem inflammatory syndrome (MIS-C) | |
650 | 4 | |a Kawasaki disease (KD) | |
650 | 4 | |a Hyperinflammation | |
650 | 4 | |a Coronavirus disease 2019 | |
650 | 4 | |a Kawasaki-like disease | |
700 | 1 | |a Pilania, Rakesh Kumar |0 (orcid)0000-0002-9015-1704 |4 aut | |
700 | 1 | |a Karkhele, Reena |0 (orcid)0000-0002-3405-5996 |4 aut | |
700 | 1 | |a Kumar, T. Sathish |0 (orcid)0000-0003-2137-7475 |4 aut | |
700 | 1 | |a Danda, Debashish |0 (orcid)0000-0002-2121-0942 |4 aut | |
700 | 1 | |a Singh, Surjit |0 (orcid)0000-0002-6716-1883 |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Rheumatology international |d Springer Berlin Heidelberg, 1981 |g 41(2020), 1 vom: 21. Nov., Seite 19-32 |w (DE-627)129098183 |w (DE-600)8286-7 |w (DE-576)014434903 |x 0172-8172 |7 nnns |
773 | 1 | 8 | |g volume:41 |g year:2020 |g number:1 |g day:21 |g month:11 |g pages:19-32 |
856 | 4 | 1 | |u https://doi.org/10.1007/s00296-020-04749-4 |z lizenzpflichtig |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_OLC | ||
951 | |a AR | ||
952 | |d 41 |j 2020 |e 1 |b 21 |c 11 |h 19-32 |